Solara Active Pharma Q2 FY27: Revenue up 33% YoY

What Solara disclosed under SEBI LODR

Solara Active Pharma Sciences disclosed an investor communication update under Regulation 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company said it uploaded the audio recording of its Q2 FY27 earnings call on October 16, 2026. The call covered unaudited financial results for the quarter ended September 30, 2026. Solara indicated that the recording is hosted on its website under the Investor Relations section for shareholder access. The disclosure ties directly to the company’s regular practice of sharing earnings-related materials, including results releases and quarterly investor presentations. Management also indicated that the transcript would be available on the company’s website in about a week’s time. The development matters for investors because it provides an official, searchable record of management commentary around performance drivers and operational issues.

Earnings call schedule and access details

The conference call was conducted at 4:00 pm IST on October 16, 2026, as a group meet for analysts and investors. Solara had earlier communicated the schedule on its investor relations website and provided dial-in numbers for participation. The company positioned the call as a discussion of Q2 FY27 unaudited results as well as the half-year ended September 30, 2026. Analysts listed as participants in the transcript coverage included Vandit Dharamshi of Memora Advisory Private Limited and Nishant Bhatt of Equity Works Limited. The operator also stated the call was being recorded, aligning with the later upload of the audio file. For investors who did not attend live, the uploaded audio serves as the primary reference for the quarter’s commentary.

Q2 FY27 performance: best quarter in about five years

Management said Q2 FY27 was the company’s best quarter in about five years on key profitability metrics including gross margin, EBITDA, and profit after tax (PAT). Overall revenue was stated at about INR 418 crore, representing 33% year-on-year growth. EBITDA more than doubled to about INR 77 crore, up 118% year-on-year, as cited in the call. PAT was reported at about INR 28.5 crore versus a loss of around INR 10 crore in the same quarter last year, based on management commentary. In the results statement figures referenced alongside the call, revenue from operations was reported at Rs 417.34 crore versus Rs 313.54 crore, up about 33.1% year-on-year, and PAT improved to Rs 29.61 crore from a loss of Rs 10.08 crore. The call framed the quarter’s gains as broad-based across profitability measures, while also noting persistent operating challenges.

What management said drove the improvement

Solara said the quarter was delivered even as the West Asia crisis continued, which it linked to input cost pressures and supply constraints. Management highlighted continued pricing pressure and raw material availability challenges that led to intermittent production stoppages. Despite these constraints, the company said it was able to post stronger results, helped by a higher flow-through from gross margin to EBITDA. The company also pointed to stable operating costs as a support for margin expansion. It stated that operating costs were sustained at roughly INR 120 crore, described as predominantly flat over the previous few quarters. This stability meant incremental gross margin contributed more directly to EBITDA for the quarter. Management also indicated that regulated markets continued to form a large share of revenue, supporting product mix quality.

Base business: revenue above INR 300 crore for third straight quarter

Management said the base business continued to lead growth. Base business revenue rose 37% year-on-year to INR 327 crore, staying above the INR 300 crore mark for the third quarter in a row. EBITDA for the base business was stated at INR 77 crore, up 68% year-on-year, with margin up by about 440 basis points to 23.6%. Solara also said regulated markets contributed about 78% of revenues, which it described as reflecting a healthy product mix. These figures suggest that the quarter’s improvement was not limited to a single product line, but was supported by stronger base operations. At the same time, the company’s commentary acknowledged that pressures on pricing and inputs remained in the background. The combination of growth and mix was presented as a key contributor to improved profitability.

Ibuprofen business: revenue up, losses narrowed to near breakeven

On the ibuprofen segment, management said performance was better than expectations, driven primarily by market dynamics. Ibuprofen revenue grew 21% year-on-year and 18% quarter-on-quarter to INR 91 crore. The improvement was attributed to better price realizations and higher volumes. Management also said the EBITDA loss in ibuprofen narrowed materially, describing the business as almost breakeven versus roughly an INR 9 crore loss in Q1. This segment commentary is important because the ibuprofen business was positioned as moving from loss-making toward breakeven in a short period. However, the company’s statements remained rooted in the quarter’s outcome and did not provide forward guidance in the provided material. The segment-level trajectory was presented as a meaningful contributor to the overall better quarter.

Margins, costs, and exceptional item: key details

Solara said the business clocked a gross margin of about INR 197 crore in Q2 FY27. It described this as roughly 28% higher year-on-year and 9% higher quarter-on-quarter, with a gross margin profile of 47.2%. Management said the gross margin profile was slightly higher than Q1 but about 200 basis points lower than last year, attributing the change largely to incremental raw material and input costs linked to the West Asia situation. On profitability, the company stated overall EBITDA margin expanded to 18.4% from about 11% last year, an improvement of roughly 720 basis points year-on-year, and up close to 200 basis points versus Q1 FY27. Depreciation was stated at about INR 26.6 crore for the quarter. Net finance cost was said to have dropped by about INR 2.7 crore, a reduction of roughly 17%, linked to a debt reduction of close to INR 114 crore during S1. The company also recorded an exceptional loss item of about INR 4.5 crore, attributed to the sale of unutilized equipment at its Vizag facility to recover cash.

EPS discussion: reported and adjusted view

Management said PAT for Q2 FY27 was the highest in the last five years and described it as roughly 75% higher on a quarter-on-quarter basis, resulting in earnings per share (EPS) of INR 5.92 per share. It also noted that adjusting for the exceptional item, EPS would have been better by close to INR 1 per share. The adjustment discussion is relevant because it separates operating performance from a one-time loss related to asset disposal. Still, the company presented the exceptional loss in the same breath as cash recovery, linking it to capital rationalisation at Vizag. Investors typically watch these adjustments closely to understand underlying earnings capacity. The company’s statement kept the focus on disclosed numbers and the specific reason for the exceptional charge.

Key data snapshot

Why the disclosure matters for investors

The immediate investor value is accessibility: the uploaded audio provides a direct record of management’s explanation of quarterly performance, including segment trends and the effect of external disruptions. The call commentary also connects profitability improvement to specific drivers like stable operating costs, better ibuprofen realizations, and a higher flow-through from gross margin to EBITDA. At the same time, management flagged ongoing constraints such as raw material availability and intermittent stoppages, which helps investors contextualise the quarter’s execution risk. The finance cost reduction and debt reduction figure give additional detail on how balance sheet actions are affecting reported earnings. The exceptional loss linked to the Vizag asset sale is a reminder that reported PAT includes non-recurring items that can shift quarter-to-quarter. For shareholders tracking the stock’s operating trajectory, this combination of numbers and commentary forms the core of the Q2 FY27 narrative.

Conclusion

Solara Active Pharma Sciences’ Q2 FY27 earnings call, now available as an audio recording on the company website, highlighted a sharp year-on-year improvement in revenue, EBITDA, and PAT for the quarter ended September 30, 2026. Management cited segment strength in the base business and a better quarter for ibuprofen, while also acknowledging input and supply disruptions linked to the West Asia crisis. The company also flagged a one-time exceptional loss tied to the sale of unutilized equipment at Vizag and noted lower finance costs following debt reduction. As indicated during the call, the company said the transcript would be available on its website in about a week, adding another reference point for investors reviewing Q2 FY27 performance.